Európska únia - slovenčina - EMA (European Medicines Agency)

stada arzneimittel ag - teriparatid - osteoporóza - homeostáza vápnika - movymia je indikovaná u dospelých. liečba osteoporózy u postmenopauzálnych žien a u mužov so zvýšeným rizikom zlomeniny. u žien po menopauze, preukázalo významné zníženie incidencie stavcov a iné zlomeniny stavcov, ale nie zlomenín. liečba osteoporózy spojené s trvalým systémové glukokortikoidy terapie u žien a mužov, zvýšené riziko zlomeniny.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

stada arzneimittel ag, nemecko - gemcitabín - 44 - cytostatica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

stada arzneimittel ag, nemecko - gemcitabín - 44 - cytostatica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

stada arzneimittel ag, nemecko - temozolomid - 44 - cytostatica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

stada arzneimittel ag, nemecko - kyselina zoledrónová - 87 - varia i

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

stada arzneimittel ag, nemecko - gemcitabín - 44 - cytostatica

Európska únia - slovenčina - EMA (European Medicines Agency)

mundipharma corporation (ireland) limited - pegfilgrastím - neutropénia - immunostimulants, - zníženie trvania neutropénie a výskytu febrilnej neutropénie u dospelých pacientov liečených cytotoxickou chemoterapiou kvôli malígnemu (s výnimkou chronickej myeloidnej leukémie a myelodysplastických syndrómov).

Európska únia - slovenčina - EMA (European Medicines Agency)

stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastické činidlá - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. Ďalšie informácie o stave receptora ľudského epidermálneho rastového faktora 2 (her2) nájdete v časti 5. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. Ďalšie informácie o stave her2 nájdete v časti 5. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Európska únia - slovenčina - EMA (European Medicines Agency)

stada arzneimittel ag - budesonide, micronised - glomerulonephritis, iga - antidiarrheals, črevné protizápalové / antiinfective agentov - kinpeygo is indicated for the treatment of primary immunoglobulin a (iga) nephropathy (igan) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (upcr) ≥1. 5 g/gram.

Európska únia - slovenčina - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologiká - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).